secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001641172-25-017288
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Processa Pharmaceuticals Announces Strategic Portfolio Review, Pipeline Realignment, and $7M Capital Infusion
--------------------------------------------------------------------------------

- Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.
- Signed binding term sheet with Intact Therapeutics granting exclusive option to license PCS12852; eligible for up to $454M milestones and 12% royalty.
- Continues enrolling patients in Phase 2 study of PCS6422 (NGC-Cap) for metastatic breast cancer; interim data expected H2 2025.
- Strengthened balance sheet with $7 million capital infusion.
- Establishing dedicated subsidiary for PCS499; designing new adaptive pivotal Phase III study for rare kidney disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000164117225017288/0001641172-25-017288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000164117225017288/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer